Evidence map›Paper›PMID 39807328›Full record

ArticleActa pharmaceutica Sinica. B2024

Controlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer

Heung Jin Jeon, Daejin Lim, EunA So, Solbi Kim, Jae-Ho Jeong, Miryoung Song, Hyo-Jin Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. AttenuatedFrontiers in immunology · 2026
    Review
  6. Optimization Strategies and Synergistic Applications of EngineeredInternational journal of nanomedicine · 2026
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heung Jin JeonInfection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea.
Daejin LimDivision of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea.
EunA SoDepartment of Microbiology, Chonnam National University Medical School, Gwangju 58128, Republic of Korea.
Solbi KimDepartment of Medical Science, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea.
Jae-Ho JeongDepartment of Microbiology, Chonnam National University Medical School, Gwangju 58128, Republic of Korea.
Miryoung SongDepartment of Bioscience and Biotechnology, Hankuk University of Foreign Studies, Yongin 17035, Republic of Korea.
Hyo-Jin LeeInfection Control Convergence Research Center, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination therapy with checkpoint inhibitors blocks inhibitory immune cell signaling and improves clinical responses to anticancer treatments. However, continued development of innovative and controllable delivery systems for immune-stimulating agents is necessary to optimize clinical responses. Herein, we engineered

Indexed as

Checkpoint inhibitorGranulocyte macrophage colony stimulating factorProgrammed death-ligand 1Salmonella

Identifiers

PMID39807328
PMCPMC11725042

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.